EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study

Elisabeth A Lasater, Dhara N Amin, Rajat Bannerji, Raghuveer Singh Mali, Kathy Barrett, Ryan N Rys, Jason Oeh, Eva Lin, Tim Sterne-Weiler, Ellen Rei Ingalla, MaryAnn Go, Shang-Fan Yu und 26 weitere

American Journal of Hematology · 2023-03 · 98 (3) · 449-463

DOI: 10.1002/ajh.26809 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift American Journal of Hematology, online erschienen am 17.01.2023. Verfasst von Elisabeth A Lasater und 37 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Oncology, Genentech, Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Lymphoma, Non-Hodgkin, Immunoconjugates. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment of patients with relapsed or refractory lymphoid neoplasms represents a significant clinical challenge. Here, we identify the pro‐survival BCL‐2 protein family member MCL‐1 as a resistance factor for the BCL‐2 inhibitor venetoclax in non‐Hodgkin lymphoma (NHL) cell lines and primary NHL samples. Mechanistically, we show that the antibody‐drug conjugate polatuzumab vedotin promotes MCL‐1 degradation via the ubiquitin/proteasome system. This targeted MCL‐1 antagonism, when combined with venetoclax and the anti‐CD20 antibodies obinutuzumab or rituximab, results in tumor regressions in preclinical NHL models, which are sustained even off‐treatment. In a Phase Ib clinical trial (NCT02611323) of heavily pre‐treated patients with relapsed or refractory NHL, 25/33 (76%) patients with follicular lymphoma and 5/17 (29%) patients with diffuse large B‐cell lymphoma achieved complete or partial responses with an acceptable safety profile when treated with the recommended Phase II dose of polatuzumab vedotin in combination with venetoclax and an anti‐CD20 antibody.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Non-HodgkinImmunoconjugatesHumansMyeloid Cell Leukemia Sequence 1 ProteinAntineoplastic Combined Chemotherapy ProtocolsRituximabAntibodies, MonoclonalSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Substanzen

Myeloid Cell Leukemia Sequence 1 ProteinRituximabImmunoconjugatespolatuzumab vedotinAntibodies, MonoclonalvenetoclaxSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Department of Translational Oncology, Genentech, Inc., South San Francisco, California, USA.
  • Department of Discovery Oncology, Genentech, Inc., South San Francisco, California, USA.
  • Department of Early Discovery Biochemistry, Genentech, Inc., South San Francisco, California, USA.
  • Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
  • Department of Biomarker Development, Genentech, Inc., South San Francisco, California, USA.
  • Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.

ORCID-Profile: Tycel Phillips, Ingrid E Wertz

Zitieren

APA

Lasater, E. A., Amin, D. N., Bannerji, R., Mali, R. S., Barrett, K., Rys, R. N., Oeh, J., Lin, E., Sterne-Weiler, T., Ingalla, E. R., Go, M., Yu, S. F., Krem, M. M., Arthur, C., Hahn, U., Johnston, A., Karur, V., Khan, N., Marlton, P., …, & Wertz, I. E. (2023). Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study. American Journal of Hematology, 98(3), 449-463. https://doi.org/10.1002/ajh.26809

Vancouver

Lasater EA, Amin DN, Bannerji R, Mali RS, Barrett K, Rys RN, et al. Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study. American Journal of Hematology. 2023;98(3):449-463. doi:10.1002/ajh.26809

BibTeX
@article{Lasater2023,
  author = {Lasater, Elisabeth A and Amin, Dhara N and Bannerji, Rajat and Mali, Raghuveer Singh and Barrett, Kathy and Rys, Ryan N and Oeh, Jason and Lin, Eva and Sterne-Weiler, Tim and Ingalla, Ellen Rei and Go, MaryAnn and Yu, Shang-Fan and Krem, Maxwell M and Arthur, Chris and Hahn, Uwe and Johnston, Anna and Karur, Vinit and Khan, Nadia and Marlton, Paula and Phillips, Tycel and Gritti, Giuseppe and Seymour, John F and Tani, Monica and Yuen, Sam and Martin, Scott and Chang, Matthew T and Rose, Christopher M and Pham, Victoria C and Polson, Andrew G and Chang, YiMeng and Wever, Claudia and Johnson, Nathalie A and Jiang, Yanwen and Hirata, Jamie and Sampath, Deepak and Musick, Lisa and Flowers, Christopher R and Wertz, Ingrid E},
  title = {Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study},
  journal = {American Journal of Hematology},
  year = {2023},
  volume = {98},
  number = {3},
  pages = {449--463},
  doi = {10.1002/ajh.26809}
}
Kostenlos starten →